TDMS Study 99022-02 Pathology Tables
NTP Experiment-Test: 99022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: PERINATAL EXPOS AZT TRANSPLACENTAL CARCINOGENESIS STUDY Date: 10/08/03
Route: IN-UTERO Time: 15:46:37
FINAL/MICE
Facility: Southern Research Institute
Chemical CAS #: 30516-87-1
Lock Date: 06/20/02
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Merge 001 001,011
Merge 002 002,012
Merge 003 003,013
Merge 004 004,014
Merge 005 005,015
Merge 006 006,016
Merge 007 007,017
Merge 008 008,018
Merge 009 009,019
Merge 010 010,020
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 99022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: PERINATAL EXPOS AZT TRANSPLACENTAL CARCINOGENESIS STUDY Date: 10/08/03
Route: IN-UTERO Time: 15:46:37
____________________________________________________________________________________________________________________________________
SWISS MICE FEMALE 0 50 100 200 300
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 40 42
Early Deaths
Moribund Sacrifice 16 18 11 11 15
Natural Death 14 13 15 9 8
Accidently Killed 1
Survivors
Moribund Sacrifice 1 1
Terminal Sacrifice 19 17 24 19 18
Natural Death 1 1
Animals Examined Microscopically 50 50 50 40 42
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Rectum (49) (48) (49) (40) (40)
Intestine Large, Cecum (47) (48) (45) (38) (40)
Leiomyosarcoma 1 (3%)
Intestine Small, Duodenum (50) (50) (48) (40) (42)
Intestine Small, Jejunum (46) (49) (46) (40) (40)
Histiocytic Sarcoma 1 (2%) 1 (3%)
Intestine Small, Ileum (47) (48) (45) (38) (40)
Liver (50) (50) (50) (40) (42)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma 2 (4%) 1 (2%) 2 (5%)
Hepatocellular Adenoma 2 (4%) 3 (6%) 4 (8%) 2 (5%) 2 (5%)
Hepatocellular Adenoma, Multiple 1 (2%) 1 (2%) 1 (2%) 2 (5%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (3%) 2 (5%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Plasma Cell Tumor Malignant 1 (2%) 1 (2%)
Mesentery (4) (8) (7) (3) (5)
Fibrosarcoma, Metastatic, Skin 1 (13%)
Hemangioma 1 (14%)
Histiocytic Sarcoma 1 (20%)
Plasma Cell Tumor Malignant 1 (13%)
Pancreas (50) (49) (49) (40) (41)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (49) (49) (40) (42)
Stomach, Forestomach (50) (50) (49) (40) (42)
Page 2
NTP Experiment-Test: 99022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: PERINATAL EXPOS AZT TRANSPLACENTAL CARCINOGENESIS STUDY Date: 10/08/03
Route: IN-UTERO Time: 15:46:37
____________________________________________________________________________________________________________________________________
SWISS MICE FEMALE 0 50 100 200 300
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Squamous Cell Papilloma 1 (2%) 1 (2%)
Stomach, Glandular (50) (50) (49) (40) (42)
Carcinoid Tumor Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (3) (2)
Heart (50) (49) (50) (40) (42)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Plasma Cell Tumor Malignant 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (50) (38) (42)
Carcinoma 1 (3%)
Plasma Cell Tumor Malignant 1 (2%)
Subcapsular, Adenoma 1 (2%) 1 (2%)
Adrenal Medulla (50) (49) (50) (38) (42)
Plasma Cell Tumor Malignant 1 (2%)
Islets, Pancreatic (50) (49) (49) (40) (41)
Adenoma 1 (3%) 2 (5%)
Parathyroid Gland (45) (45) (48) (37) (36)
Adenoma 1 (2%)
Pituitary Gland (50) (49) (50) (40) (42)
Pars Distalis, Adenoma 1 (2%) 1 (2%) 1 (3%) 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (49) (50) (40) (42)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 99022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: PERINATAL EXPOS AZT TRANSPLACENTAL CARCINOGENESIS STUDY Date: 10/08/03
Route: IN-UTERO Time: 15:46:37
____________________________________________________________________________________________________________________________________
SWISS MICE FEMALE 0 50 100 200 300
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (50) (50) (50) (40) (42)
Ovary (50) (50) (49) (40) (42)
Cystadenoma 2 (4%) 1 (2%) 2 (4%) 1 (2%)
Granulosa Cell Tumor Malignant 2 (5%) 1 (2%)
Hemangioma 1 (3%)
Hemangiosarcoma 1 (2%)
Luteoma 1 (2%)
Plasma Cell Tumor Malignant 1 (2%)
Sertoli Cell Tumor Benign 1 (2%)
Uterus (50) (50) (49) (40) (42)
Hemangioma 1 (2%) 1 (3%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (5%)
Leiomyoma 1 (2%) 1 (2%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 1 (2%) 1 (2%) 1 (2%) 1 (3%) 1 (2%)
Vagina (49) (49) (47) (40) (41)
Plasma Cell Tumor Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (40) (42)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Plasma Cell Tumor Malignant 1 (2%)
Lymph Node (14) (23) (16) (12) (16)
Histiocytic Sarcoma 1 (4%)
Plasma Cell Tumor Malignant 1 (6%)
Deep Cervical, Plasma Cell Tumor Malignant 1 (6%)
Iliac, Histiocytic Sarcoma 1 (4%)
Iliac, Plasma Cell Tumor Malignant 1 (6%)
Inguinal, Plasma Cell Tumor Malignant 1 (6%)
Mediastinal, Histiocytic Sarcoma 1 (6%) 1 (6%)
Mediastinal, Plasma Cell Tumor Malignant 2 (9%) 1 (6%)
Pancreatic, Hemangioma 1 (6%)
Pancreatic, Plasma Cell Tumor Malignant 1 (6%)
Popliteal, Plasma Cell Tumor Malignant 1 (6%)
Renal, Histiocytic Sarcoma 1 (4%)
Renal, Plasma Cell Tumor Malignant 1 (4%) 1 (6%)
Lymph Node, Mandibular (49) (47) (49) (40) (42)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Plasma Cell Tumor Malignant 1 (2%) 1 (2%)
Page 4
NTP Experiment-Test: 99022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: PERINATAL EXPOS AZT TRANSPLACENTAL CARCINOGENESIS STUDY Date: 10/08/03
Route: IN-UTERO Time: 15:46:37
____________________________________________________________________________________________________________________________________
SWISS MICE FEMALE 0 50 100 200 300
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lymph Node, Mesenteric (50) (48) (46) (40) (42)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (5%)
Plasma Cell Tumor Malignant 1 (2%) 1 (2%)
Spleen (50) (50) (49) (40) (42)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Plasma Cell Tumor Malignant 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Thymus (49) (44) (46) (36) (42)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (3%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (5%)
Plasma Cell Tumor Malignant 2 (5%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (49) (40) (42)
Carcinoma 2 (4%) 2 (4%) 2 (4%) 1 (3%) 1 (2%)
Skin (50) (50) (49) (40) (42)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (2%) 1 (3%)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%) 1 (3%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (40) (42)
Osteoma 1 (2%) 1 (3%)
Osteosarcoma 1 (2%)
Skeletal Muscle (5) (2) (1) (1) (4)
Sarcoma 1 (20%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (40) (42)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Spinal Cord (50) (50) (50) (40) (42)
Page 5
NTP Experiment-Test: 99022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: PERINATAL EXPOS AZT TRANSPLACENTAL CARCINOGENESIS STUDY Date: 10/08/03
Route: IN-UTERO Time: 15:46:37
____________________________________________________________________________________________________________________________________
SWISS MICE FEMALE 0 50 100 200 300
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM - cont
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (49) (50) (40) (42)
Alveolar/Bronchiolar Adenoma 7 (14%) 3 (6%) 7 (14%) 4 (10%) 7 (17%)
Alveolar/Bronchiolar Adenoma, Multiple 3 (6%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 4 (8%) 6 (12%) 6 (12%) 4 (10%) 3 (7%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 2 (4%) 4 (10%) 2 (5%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Granulosa Cell Tumor Malignant, Metastatic,
Lung 1 (3%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (3%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Plasma Cell Tumor Malignant 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Nose (50) (50) (50) (40) (42)
Histiocytic Sarcoma 1 (3%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (49) (49) (50) (40) (41)
Adenoma 4 (8%) 6 (12%) 9 (18%) 4 (10%) 7 (17%)
Carcinoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (3%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (40) (42)
Histiocytic Sarcoma 1 (3%)
Plasma Cell Tumor Malignant 1 (2%) 1 (2%)
Urinary Bladder (50) (50) (49) (40) (42)
Histiocytic Sarcoma 1 (3%)
Page 6
NTP Experiment-Test: 99022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: PERINATAL EXPOS AZT TRANSPLACENTAL CARCINOGENESIS STUDY Date: 10/08/03
Route: IN-UTERO Time: 15:46:37
____________________________________________________________________________________________________________________________________
SWISS MICE FEMALE 0 50 100 200 300
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(40) *(42)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) 2 (5%) 2 (5%)
Leukemia Granulocytic 1 (2%) 1 (2%)
Lymphoma Malignant 19 (38%) 19 (38%) 20 (40%) 16 (40%) 17 (40%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 7
NTP Experiment-Test: 99022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: PERINATAL EXPOS AZT TRANSPLACENTAL CARCINOGENESIS STUDY Date: 10/08/03
Route: IN-UTERO Time: 15:46:37
____________________________________________________________________________________________________________________________________
SWISS MICE FEMALE 0 50 100 200 300
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 35 33 38 31 33
Total Primary Neoplasms 55 76 85 48 57
Total Animals with Benign Neoplasms 17 17 23 14 16
Total Benign Neoplasms 19 27 32 16 23
Total Animals with Malignant Neoplasms 30 28 31 25 27
Total Malignant Neoplasms 36 49 53 32 34
Total Animals with Metastatic Neoplasms 1 2 3 2 1
Total Metastatic Neoplasm 2 4 6 2 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 8
NTP Experiment-Test: 99022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: PERINATAL EXPOS AZT TRANSPLACENTAL CARCINOGENESIS STUDY Date: 10/08/03
Route: IN-UTERO Time: 15:46:37
____________________________________________________________________________________________________________________________________
SWISS MICE MALE 0 50 100 200 300
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 37 32
Early Deaths
Moribund Sacrifice 24 20 25 23 12
Natural Death 7 9 11 5 10
Accidently Killed 1 1 2
Survivors
Terminal Sacrifice 19 20 13 7 7
Moribund Sacrifice 1
Natural Death 1
Other 1
Animals Examined Microscopically 50 50 50 37 32
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (45) (46) (46) (33) (27)
Intestine Large, Colon (48) (50) (49) (37) (32)
Intestine Large, Cecum (49) (49) (48) (35) (30)
Intestine Small, Duodenum (49) (50) (49) (36) (32)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (49) (50) (46) (36) (29)
Intestine Small, Ileum (49) (48) (47) (35) (30)
Liver (50) (50) (50) (37) (32)
Hemangiosarcoma 7 (14%) 4 (8%) 3 (6%) 1 (3%) 3 (9%)
Hepatoblastoma 1 (2%) 2 (4%)
Hepatocellular Carcinoma 4 (8%) 5 (10%) 5 (10%) 2 (5%) 1 (3%)
Hepatocellular Carcinoma, Multiple 2 (4%) 1 (2%) 1 (2%) 2 (5%) 1 (3%)
Hepatocellular Adenoma 12 (24%) 5 (10%) 5 (10%) 5 (14%) 4 (13%)
Hepatocellular Adenoma, Multiple 2 (4%) 6 (12%) 5 (10%) 3 (8%)
Hepatocholangiocarcinoma 1 (3%)
Pancreas (50) (50) (50) (37) (31)
Salivary Glands (50) (50) (50) (37) (32)
Carcinoma 1 (2%)
Stomach, Forestomach (49) (50) (50) (37) (32)
Squamous Cell Papilloma 1 (3%)
Stomach, Glandular (49) (50) (50) (37) (32)
Adenoma 1 (3%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 99022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: PERINATAL EXPOS AZT TRANSPLACENTAL CARCINOGENESIS STUDY Date: 10/08/03
Route: IN-UTERO Time: 15:46:37
____________________________________________________________________________________________________________________________________
SWISS MICE MALE 0 50 100 200 300
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (37) (32)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
Sarcoma 1 (3%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (37) (32)
Adenoma 2 (4%) 1 (2%) 1 (3%)
Subcapsular, Adenoma 2 (5%)
Adrenal Medulla (50) (50) (49) (37) (32)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (50) (50) (36) (31)
Adenoma 1 (2%)
Pituitary Gland (48) (49) (49) (36) (31)
Schwannoma Malignant, Metastatic, Brain 1 (2%) 1 (2%)
Pars Distalis, Adenoma 1 (2%)
Thyroid Gland (50) (50) (50) (37) (32)
Follicular Cell, Adenoma 1 (3%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (37) (32)
Prostate (50) (50) (50) (37) (32)
Seminal Vesicle (50) (50) (50) (37) (32)
Testes (50) (50) (50) (37) (32)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Bilateral, Interstitial Cell, Carcinoma 1 (3%)
Interstitial Cell, Adenoma 1 (3%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 99022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: PERINATAL EXPOS AZT TRANSPLACENTAL CARCINOGENESIS STUDY Date: 10/08/03
Route: IN-UTERO Time: 15:46:37
____________________________________________________________________________________________________________________________________
SWISS MICE MALE 0 50 100 200 300
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (37) (32)
Hemangiosarcoma 1 (2%)
Lymph Node (12) (10) (15) (6) (2)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (17%)
Mediastinal, Hemangiosarcoma 1 (7%)
Lymph Node, Mandibular (50) (50) (49) (37) (32)
Lymph Node, Mesenteric (50) (49) (49) (36) (32)
Spleen (49) (50) (50) (37) (32)
Hemangiosarcoma 3 (6%) 2 (4%) 1 (2%) 1 (3%)
Thymus (48) (45) (47) (33) (32)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (37) (32)
Squamous Cell Papilloma 1 (3%)
Subcutaneous Tissue, Basal Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (3%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (37) (32)
Schwannoma Malignant, Metastatic, Brain 1 (2%)
Skeletal Muscle (1) (2) (1) (3) (2)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (50%) 1 (33%) 1 (50%)
Hemangioma 1 (50%)
Hemangiosarcoma 1 (33%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (49) (50) (50) (37) (32)
Oligodendroglioma Malignant 1 (3%)
Schwannoma Malignant 1 (2%)
Cranial Nerve, Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 99022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: PERINATAL EXPOS AZT TRANSPLACENTAL CARCINOGENESIS STUDY Date: 10/08/03
Route: IN-UTERO Time: 15:46:37
____________________________________________________________________________________________________________________________________
SWISS MICE MALE 0 50 100 200 300
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (37) (32)
Alveolar/Bronchiolar Adenoma 7 (14%) 13 (26%) 8 (16%) 8 (22%) 10 (31%)
Alveolar/Bronchiolar Adenoma, Multiple 3 (6%) 1 (3%) 1 (3%)
Alveolar/Bronchiolar Carcinoma 4 (8%) 6 (12%) 5 (10%) 5 (14%) 5 (16%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 5 (10%) 1 (2%) 6 (16%) 3 (9%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Nose (50) (50) (50) (36) (32)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (50) (50) (49) (37) (32)
Adenoma 11 (22%) 8 (16%) 9 (18%) 3 (8%) 4 (13%)
Carcinoma 1 (2%) 1 (3%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (37) (32)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (50) (50) (50) (37) (32)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(37) *(32)
Lymphoma Malignant 6 (12%) 9 (18%) 7 (14%) 4 (11%) 3 (9%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 99022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: PERINATAL EXPOS AZT TRANSPLACENTAL CARCINOGENESIS STUDY Date: 10/08/03
Route: IN-UTERO Time: 15:46:37
____________________________________________________________________________________________________________________________________
SWISS MICE MALE 0 50 100 200 300
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 35 35 34 25 26
Total Primary Neoplasms 68 71 61 51 40
Total Animals with Benign Neoplasms 27 23 27 18 16
Total Benign Neoplasms 39 35 30 27 20
Total Animals with Malignant Neoplasms 19 27 20 20 17
Total Malignant Neoplasms 29 36 31 24 20
Total Animals with Metastatic Neoplasms 2 1 1 1 1
Total Metastatic Neoplasm 2 1 2 3 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------